Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04188522 · ClinicalTrials.gov registry record

Imaging Post-Stroke Recovery: Using MEG to Evaluate Cognition

A clinical trial of Stroke and Stroke Sequelae, sponsored by Johns Hopkins University.

Recruiting
Registry status
55
Enrollment target
1
Study location

NCT04188522: Recruiting study of Stroke and Stroke Sequelae, sponsored by Johns Hopkins University.

NCT04188522 is a study of Stroke and Stroke Sequelae that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 55 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04188522, a study of Stroke and Stroke Sequelae, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
55 participants
Enrollment target
1
Study location

Study Summary

This is a study using magnetoencephalography (MEG) to look at recovery in those with minor stroke. The investigators know that these individuals report difficulties in attention, concentration, multi-tasking, energy level, and processing speed that appear to be independent of lesion size or location. The underlying pathophysiology is unclear; however, anecdotally, many individuals are significantly improved by 6 months post-stroke. One hypothesis is that a single lesion, regardless of size, may disrupt the classic neural networks required for cognitive function. The investigators are currently collecting data to better characterize these difficulties and stroke patients' recovery as part of a previously approved recovery study. In this sub-study, the investigators propose to add MEG at 1 and 6 months in a subset of individuals with small: 1) subcortical, and 2) cortical lesions. The investigators will partner with colleagues at the University of Maryland (College Park), who are well experienced with MEG to conduct this research. In addition a control population of age-similar individuals will be recruited for comparison. Cerebral activation patterns of individuals with stroke versus controls will be compared, both across patients with stroke at a given time point, and within subjects from 1 to 6 months to determine the association of abnormal activation with cognitive dysfunction and recovery. \*\*The investigators have recently extended follow-up by adding an additional assessment at 12 months and will enroll additional participants (up to 40 patients with minor stroke, 15 age-similar controls).

Primary Outcome

Global patterns of cerebral activity as well as individual brain areas important for cognitive processing will be analyzed for differences with respect to amplitude, latency, and frequency.

Interventions

  • DIAGNOSTIC_TEST Magnetoencephalography (MEG)

Study Locations (1)

Maryland

  • Johns Hopkins Bayview Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2018-07-01
Est. Completion 2026-06-30
Johns Hopkins University

1,448 total trials

What NCT04188522 shows while recruiting

NCT04188522 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).

The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Magnetoencephalography (MEG) is the first listed.

NCT04188522 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT04188522 about?

NCT04188522 is a clinical study titled "Imaging Post-Stroke Recovery: Using MEG to Evaluate Cognition". This is a study using magnetoencephalography (MEG) to look at recovery in those with minor stroke. The investigators know that these individuals report difficulties in attention, concentration, multi-tasking, energy level, and processing speed that appear to be independent of lesion size or location...

What is the current status of trial NCT04188522?

This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2018-07-01. Estimated completion is 2026-06-30.

What conditions does trial NCT04188522 study?

This clinical trial studies the following conditions: Stroke, Stroke Sequelae, Stroke/Brain Attack.

What interventions are being tested in trial NCT04188522?

The interventions under investigation include: Magnetoencephalography (MEG) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04188522?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04188522 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04188522's enrollment target sits among peer trials

55 225th of 454 higher than 228 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04188522, the US trial registry maintained by the National Library of Medicine. NCT04188522 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.